Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers in the world. The prognosis of patients with ESCC is dismal with a 5-year survival of about 15%. Thus, identification of novel diagnostic and prognostic biomarkers for ESCC patients is urgently needed. Here, we found that manipulation of I-branching N-acetylglucosaminyltransferase (GCNT2) expression had no effect on cell proliferation. Notably, overexpression of GCNT2 promoted the migration and invasion, and this effect was associated with increased expression of N-cadherin and vimentin and decreased expression of E-cadherin in KYSE30 and EC9706 cells. Knockdown of GCNT2 decreased the expression of N-cadherin and vimentin, increased the expression of E-cadherin, and inhibited the migration and invasion in KYSE150 and EC109 cells. The expression of GCNT2 was significantly higher in tumour tissues than in paratumour tissues through tissue microarray analysis. More importantly, overall survival was significantly lower in patients with high GCNT2 expression than those with low GCNT2 expression. Collectively, our findings establish GCNT2 as a novel regulator of epithelial-mesenchymal transition (EMT) and a candidate prognostic indicator of outcome in ESCC patients.
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Significance of the study: Our study suggested that GCNT2 was highly expressed in patients with ESCC and predicted adverse outcome. Overexpression of GCNT2 induces EMT and promotes migration and invasion in ESCC cells. Therefore, GCNT2 may act as a candidate prognostic indicator of outcome and a novel target in ESCC patients.
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Esophageal cancer is one of the most common malignant cancers worldwide. 1 Esophageal squamous cell carcinoma (ESCC) is the major pathological type in the Chinese patients with esophageal cancer. 2 The overall 5-year survival rate for ESCC is approximately 10% to 20%, 3 which is partially due to diagnosis in later stages accompanied by local invasion and distant metastasis. 2, 4 However, the underlying List of abbreviations: GCNT2, I-branching N-acetylglucosaminyltransferase; ESCC, esophageal squamous cell carcinoma; EMT, epithelial-mesenchymal transition; IHC, immunohistochemistry; TMA, tissue microarray; shRNA, small hairpin RNA; TNM, tumour-node-metastasis; qRT-PCR, quantitative real-time polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; BSA, bovine serum albumin molecular mechanisms of metastasis in ESCC remain elusive. Therefore, there is an urgent need for identification of novel effective therapeutic targets in metastatic ESCC.
Epithelial-mesenchymal transition (EMT) is a highly conserved cellular process, which plays an important role in tumour progression, invasion, and metastasis. [5] [6] [7] In the EMT process, polarized, immobile epithelial cells change their original epithelial phenotype and adopt the features and morphology of mesenchymal cells, which acquire a spindle-shaped morphology and exhibit more invasive behaviour. 8 These phenotypic changes are generally associated with decreased expression of epithelial specific biomarkers (eg, E-cadherin) and increased expression of mesenchymal specific biomarkers (eg, N-cadherin and vimentin). 5 EMT is tightly regulated by several master transcriptional factors, such as Snail1, Slug, Twist, and ZEB1/2. 6,9,10 EMT is usually a precedent event of metastasis, drug resistance, and relapse. To better understand how EMT is regulated in ESCC may facilitate searching for potential therapeutic targets in metastatic ESCC.
Cell surface carbohydrates play a significant role in cell proliferation and invasion. 11, 12 The I-branching N-acetylglucosaminyltransferase (GCNT2), one of cell surface carbohydrates, can synthesize I-branched polylactosamine chains (I-antigen) by catalysing the transfer of N-acetylglucosamine (GlcNAc) from uridine diphosphateGlcNAc with a galactose β1-6 linkage of linear lactosamine chains. 13 It is reported that GCNT2 is implicated in tumour metastasis in several types of human cancers. [14] [15] [16] For example, GCNT2 is overexpressed in highly metastatic breast cancer cell lines and basal-like breast tumour samples. The expression of GCNT2 is directly regulated by transforming growth factor β (TGF-β)-smad pathway. Interestingly, knockdown of GCNT2 by its specific small hairpin RNA (shRNA) or inhibition of its glycosyltransferase activity in breast cancer cell lines significantly abrogates the TGF-β-induced EMT, consequently inhibits cell migration and invasion in vitro, and lung metastasis of breast cancer cells in vivo. 14 In prostate cancer, GCNT2 regulates prostate cancer invasiveness through enhancing α5β1 integrin signalling. 15 However, the role of GCNT2 in ESCC
remains enigmatic yet.
In this study, we aimed at exploring the role of GCNT2 in ESCC.
We found that overexpression of GCNT2 significantly promoted the migration and invasion of ESCC cells, while knockdown of GCNT2 by shRNA dramatically inhibited the migration and invasion. Mechanistically, GCNT2 was notably associated with EMT. Taken together, these data suggest a role of GCNT2 in the migration and invasion of ESCC. 
| Immunohistochemistry assay
Immunohistochemistry (IHC) was performed to assess the protein expression of GCNT2 in ESCC tissues and matched nontumour tissues. 17 Briefly, the TMA sections were deparaffinized and rehydrated with xylene and graded alcohol. Antigen retrieval was submerged into sodium citrate buffer and microwaved for 5 minutes.
Then, they were soaked with 3% H 2 O 2 for 15 minutes to block the endogenous peroxidase. After blocking with 5% bovine serum albumin (BSA) for 20 minutes, the slides were incubated with anti-GCNT2
(1:50, Abcam, Cambridge, Massachusetts) overnight at 4°C. After washing with ddH 2 O and PBS, the TMA sections were incubated with secondary antibody at room temperature for 1 hour. Slides were stained with diaminobenzidine (DAB) and counterstained with Note: P = 0.003 was considered statistically significant. Bold emphasis and asterisk were both used to emphasize analytical result that ESCC patients with high expression of GCNT2 had advanced tumor -node-metastasis (TNM) stage (P = 0.003).
haematoxylin. Finally, they were dehydrated with a series of grades of alcohol and mounted using neutral gum.
| Cell culture and transfection
The ESCC cell lines KYSE30, KYSE150, EC109, and EC9706 were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and were cultured in DMEM medium (Invitrogen, Shanghai, China) supplemented with 10% foetal bovine serum (FBS) (Biological Industries, Kibbutz Beit Haemek, Israel) in a 37°C humidified incubator containing 5% CO 2 .
18
Human GCNT2 (NCBI Reference Sequence ID: NM_145655.3)
were cloned into the pTSB-CMV-3Flag-copGFP-F2A-PuroR (lentivirus) construct (Transheep, Shanghai, China) using ClonExpress MultiS
One
Step Cloning Kit (Vazyme, Nanjing, China). Scramble (pLKO.1-puro-Non-target shRNA) or human GCNT2 specific target shRNA (pLKO.1-puro-GCNT2-target shRNA) were purchased from SigmaAldrich (Shanghai, China). pCMV-dR8.2 and pCMV-VSVG constructs were from Addgene (Cambridge, MA). The lentivirus packing procedure was implemented as previous description. 19 Briefly, 293T cells were transfected with the control or target lentiviral constructs together with pCMV-dR8.2 and pCMV-VSVG using polyethyleneimine (Polysciences, Inc., Warrington, Pennsylvania). Viral supernatants were collected and purified with 0.45-μm filter after 48 or 72 hours.
KYSE30 and EC9706 cells were transduced with the GCNT2-overexpressing or vector control virus-containing supernatants while KYSE150 and EC109 cells were transduced with the GCNT2-knockdown or control (Scramble) virus-containing supernatants. To establish stable clones overexpressing or silencing GCNT2, the transduced cells were selected with puromycin (1 μg/mL) for 2 weeks.
| Quantitative real-time polymerase chain reaction (qRT-PCR) analysis
Total mRNA was extracted with Trizol reagent (Invitrogen, Shanghai, China). A NanoDrop ND-1000 spectrophotometer was used to assess the concentration of mRNA. Then, the mRNA was used as templates to generate cDNA with maxima first strand cDNA synthesis kit (Thermo Scientific, Shanghai, China). Quantitative real-time RT-PCR was performed using SYBR Premix Ex Taq (Perfect Real-time, Takara Bio, Beijing, China)
according to the manufacturer's instruction in a Bio-Rad CFX96 RealTime Thermocycler (CFX96, Bio-Rad Laboratories, Hercules, CA). 19 The expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous reference. PCR primers were as follows:
GCNT2 forward: 5′-TGTTCCTGGCTCTATGCCAAA-3′
GCNT2 reversed: 5′-TTAGCAAACAGGCTTGGTGAAT-3′
GAPDH forward: 5′-GATCGAATTAAACCTTATCGTCGT-3′
GAPDH reversed: 5′-AGCAGCAGAACTTCCACTCGGT-3′
| Western blotting analysis
Western blotting analysis was performed as previously described. 20 Proteins were extracted in RIPA lysis buffer (1 × PBS, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS), which were supplemented with protease and phosphatase inhibitors (1 × protease inhibitor cocktail [Roche, Shanghai, China], 10-mM β-glycerophosphate, 1-mM sodium orthovanadate, 10-mM NaF, and 1-mM phenylmetnylsulfonyl fluoride).
Pierce BCA Protein Assay Kit (Thermo Scientific, Shanghai, China) was used to measure the protein concentration. Equal amounts of protein samples were separated by SDS-PAGE gel electrophoresis and then transferred to nitrocellulose membranes, which were then incubated with the primary antibodies overnight at 4°C. After incubation with appropriate secondary antibodies, the immunoblots were recorded with the Odyssey infrared imaging system (LI-COR). The immunoblots were quantified by using Image J software. The expression of β-actin was used as loading control. Primary antibodies against E-cadherin and β-actin were purchased from Cell Signaling Technology (Beverly, MA).
Antibodies against N-cadherin, vimentin, and Snail1 were purchased from Abcam (Cambridge, UK). Antibody against Flag was purchased from Sigma-Aldrich (Shanghai, China). Anti-mouse immunoglobulin G and anti-rabbit immunoglobulin G fluorescent-conjugated secondary antibodies were from LI-COR Biotechnology (Lincoln, Nebraska).
| Immunofluorescence staining
Immunofluorescence staining was performed as previously described. 21 In brief, after the cells ( 
| Cell growth assay
For cell proliferation, trypan blue exclusion assay was performed as previously described. 22 Briefly, 2 × 10 4 (KYSE30 and EC9706) or 5 × 10 4 (KYSE150 and EC109) cells were seeded in 6-well plates and then counted each day with exclusion of trypan blue dye by a haemocytometer.
| Plate colony-formation assay
Plate colony-formation assay was carried out as described previously. 23 In brief, 500 cells stably expressing GCNT2 or shRNAs targeting GCNT2 were seeded per well in 6-well plates and maintained in medium containing 10% FBS, which was refreshed every 2 days. After 10 to 14 days of incubation at 37°C in 5% CO 2 , the cells were fixed with 3% paraformaldehyde and stained with 0.5% crystal violet for 15 minutes. Then, the colonies in 6-well plates were photographed and counted. 
| Migration and invasion assay
The migration and invasion assays were performed as previously described. 24 For the migration assay, 2 × 10 4 cells were resuspended 
| Statistical analysis
GraphPad Prism 6.02 software (GraphPad, San Diego, California) was used for statistical analysis. The data represent mean ± standard deviation (SD). Difference between two groups was analysed using two- and statistical difference in survival was compared using the log-rank test. P < 0.05 was considered statistically significant. The experiments and assays were performed at least three times.
| RESULTS AND DISCUSSION

| Overexpressed GCNT2 predicts poor survival in patients with ESCC
First, we performed IHC analysis to examine GCNT2 expression in a tissue microarray, which contains 168 pairs of ESCC specimens and matched nontumour tissues. The staining of GCNT2, which occurred in the cell cytoplasm, was clearly observed in ESCC tissues ( Figure 1A ).
As showed in the scoring system, 1 is an example of no staining, 2 is weak staining, 3 is intermediate staining, and 4 is strong staining ( Figure 1A ). In addition, the staining of a pair of carcinoma and paracarcinoma was shown ( Figure 1B) . According to the GCNT2 immunoreactivity score, we found that the expression of GCNT2 in ESCC cancerous tissues was significantly higher than in paracarcinoma tissues (P < 0.001, Figure 1C) . To assess the clinical value of GCNT2 in ESCC, all patients were grouped into GCNT2 low (scores 1-2) and high (scores 3-4) expression groups according to the median expression of GCNT2. As shown in Table 1 , ESCC patients with high expression of GCNT2 had advanced tumour-node-metastasis (TNM) stage (P = 0.003). In contrast, GCNT2 expression displayed no association with gender, age, and histological grade (Table 1) . Furthermore, survival analysis indicated that patients with high expression of GCNT2
showed significantly poorer survival outcome (P < 0.05, Figure 1D ).
Similarly, the survival analysis on the M0 group showed the same results (P < 0.05, Figure 1E ). The survival of patients in M1 group could not be analysed because GCNT2 was highly expressed in all the 10 patients of M1 group. These data suggest that overexpressed GCNT2 predicts poor survival in patients with ESCC.
| GCNT2 induces EMT in ESCC cells
Given the critical role of GCNT2 in metastasis in breast cancer, we next investigated whether GCNT2 was associated with the EMT pro- Figure 2B ). Western blotting analysis of the EMT-associated proteins showed that the epithelial biomarker E-cadherin was downregulated, while the mesenchymal biomarkers N-cadherin and vimentin, and Snail1, a EMT-driver transcription factor, were appreciably increased in the cells stably overexpressing GCNT2 ( Figure 2C ). In addition, immunofluorescent staining analysis also suggested that E-cadherin was downregulated and vimentin was upregulated in the GCNT2-overxpressing cells, compared with control cells ( Figure 2D ). Conversely, KYSE150 and EC109 cells were transfected with GCNT2-shRNA or scramble control. Compared with scramble, transfection with shGCNT2 resulted in an obvious reduction of GCNT2 in both KYSE150 and EC109 cells, which were detected by qRT-PCR assay ( Figure 2E ). Knockdown of GCNT2 increased the expression levels of E-cadherin, whereas reduced the expression levels of N-cadherin, vimentin, and Snail1 ( Figure 2F ). Consistently, immunofluorescence data showed that E-cadherin expression was increased while vimentin expression was decreased in cells with GCNT2 depleted ( Figure 2G ). Taken together, our results indicate that GCNT2 induces EMT in ESCC cells.
| GCNT2 promotes migration and invasion without affecting cellular proliferation in ESCC
To evaluate the effect of GCNT2 on ESCC cell proliferation, trypan blue exclusion assay and colony formation assay were performed.
GCNT2-overexpressing KYSE30 and EC9706 cells exhibited a similar rate in growth and colony number compared with control ( Figure 3A,B) . These data suggest that the ectopic expression of GCNT2 may have minimal effect on the proliferation of ESCC cells.
We next measured the effect of GCNT2 on migration and invasion of ESCC cells. In wound-healing assay, the cell migration rate of GCNT2-overexpressing KYSE30 and EC9706 cells was notably increased compared with vector control cells ( Figure 3C ). Next, we used Boyden chambers and matrigel invasion chamber to test the effect of GCNT2 on cell migration and invasion. As shown in Figure 3D ,E, ectopic expression of GCNT2 in KYSE30 and EC9706 cells dramatically increased cell migration and invasion (P < 0.05, respectively). Taken together, these results suggest that overexpression of GCNT2 promotes the migration and invasion capacities of ESCC cells.
| Knockdown of GCNT2 decreases the migration and invasion of ESCC cells
We next investigated the influence of GCNT2 knockdown on cell proliferation and colony formation; trypan blue exclusion assay and colony formation assay found that there was no difference between cells with GCNT2-knockdown and scramble control ( Figure 4A,B) . Then, we checked the effect of GCNT2 knockdown on cell migration and invasion. In wound healing assay, the scratch healing was significantly inhibited in KYSE150 and EC109 cells with GCNT2 knockdown, compared with scramble ( Figure 4C ). Transwell assay revealed that knockdown of GCNT2 significantly decreased the numbers of migrated and invaded cells, respectively (P < 0.05, Figure 4D ,E).
Collectively, these data suggest that knockdown of GCNT2 decreases the migration and invasion abilities of KYSE150 and EC109 cells.
Glycosylation is a common posttranscriptional modification of proteins, 25 which is implicated in many physiologic and pathologic events. 26 In the present study, we demonstrated that the expression of GCNT2 was remarkably higher in ESCC tissues than that in
FIGURE 3
Ectopically overexpressing GCNT2 promotes migration and invasion but not cellular proliferation in ESCC cells. A, KYSE30 and EC9706 cells stably transfected with lentiviral pTSB-CMV-GCNT2-3Flag-copGFP-F2A-PuroR or empty vector were inoculated in 6-well plates to allow growth and monitored by trypan blue exclusion assay over 7 days. B, KYSE30 and EC9706 cells stably transfected with lentiviral pTSB-CMV-GCNT2-3Flag-copGFP-F2A-PuroR or empty vector were incubated in 6-well plates for 10 to 14 days, colonies were counted. Data represent mean ± SD. ns, no significance, Student t test. C, KYSE30 and EC9706 cells stably transfected with lentiviral pTSB-CMV-GCNT2-3Flag-copGFP-F2A-PuroR or empty vector were analysed for wound healing capacity. D and E, KYSE30 and EC9706 cells stably transfected with GCNT2 were examined transwell assays for migration (D) and invasion (E). The migrated and invaded cells were counted in three random fields, respectively. Data represent mean ± SD. **P < 0.01; ***P < 0.001; Student t test. Scale bar for panels C-E: 200 μm FIGURE 4 Silencing GCNT2 decreases migration and invasion in ESCC cells. A, KYSE150 and EC109 cells underwent lentiviral shRNA control (Scramble) or shRNA against human GCNT2 gene, were inoculated in 6-well plates to allow growth, and monitored by trypan blue exclusion assay over 7 days. B, Clonogenecity of KYSE150 and EC109 cells with GCNT2 knockdown were examined by colony-formation assays; colonies were counted at day 10 to 14. Data represent mean ± SD. ns, no significance, one-way ANOVA, post hoc comparisons, Tukey test. KYSE150 and EC109 cells underwent shRNA control (Scramble) or shRNA against human GCNT2 gene and subjected to wound-healing scratch assay (C) or transwell assays for migration (D) and invasion (E). The migrated and invaded cells were counted in three random fields, respectively. Data represent mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001; one-way ANOVA, post hoc comparisons, Tukey test. Scale bar for panels C-E: 200 μm.
paratumour tissues ( Figure 1C ). More importantly, GCNT2 expression was found to be significantly associated with lymph node metastases and patient outcome (Table 1 and Figure 1D ). Overall, these results indicate that GCNT2 might be a candidate prognostic indicator of poor outcome in ESCC patients and will provide clues for new targeted therapies.
EMT is a highly conserved cellular process, in which loss of E-cadherin and gain of N-cadherin and vimentin converted epithelial cells from noninvasive to invasive. Considerable evidence has demonstrated the importance of EMT in cancer progression, metastasis, and chemoresistance, which makes it an attractive target for therapeutic interventions. 27 Thus, identification of the genes that regulate EMT and metastasis may lead to the development of potential therapeutic targets in the management of cancer metastasis. Here, our study showed that overexpression of GCNT2 significantly increased, and silencing GCNT2 decreased the expression of Snail1 in ESCC cells regulates Snail1 expression and EMT in ESCCs.
In conclusion, our work established a linkage between GCNT2
and migration and invasion in ESCC. GCNT2 may be a potential biomarker and a new therapeutic target for ESCC cancer.
